Her Covert Affairs team have no influence or insight into the resourcing over all. I cant comment that we can get back to you. Thank you for your comments, congressman. So thats exactly why we are here. I speak for a section of the pharmaceutical industry that few people actually appreciate, especially given the statistics that i referenced that two out of every three new drugs approved by the fda last year actually originated in companies that are small biopharmaceutical emerging companies. We dont have a voice in washington. Excelixis is not a member of pharma. Where a number of bio. We dont hear the realities, the pains and challenges that are faced to bring an important new drug to market, represent and the debates because i think a lot of people take for granted that its all great Big Companies with huge budgets and throwing a lot of money at problems. You may be an example of someone who is at a competitive disadvantage because you dont have the same resources to deploy into thos